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Abstract
The Centre for Reviews and Dissemination and Centre for Health Economics Technology Assessment Group at the University 
of York was commissioned by the National Institute for Health and Care Excellence (NICE) Highly Specialised Technologies 
(HST) programme to act as the independent Evidence Review Group (ERG) for an appraisal of  Strimvelis®, a gene therapy 
treatment for adenosine deaminase deiciency–severe combined immunodeiciency (ADA-SCID). This paper describes the 
manufacturing company’s submission of clinical and economic evidence, the ERG’s review and the resulting NICE guidance. 
For  Strimvelis® compared with haematopoietic stem cell transplant (HSCT) from a matched unrelated donor (MUD) and 
HSCT from a haploidentical donor, the company base-case deterministic incremental cost-efectiveness ratios (ICERs) were 
£36,360 and £14,645 per quality-adjusted life-year (QALY) gained, respectively (using a discount rate of 1.5%). Although 
overall survival in patients receiving  Strimvelis® was substantially higher than historical comparator data on HSCT from a 
MUD or haploidentical donor, the ERG was concerned that the estimated treatment beneit remained highly uncertain. The 
ERG critiqued some assumptions in the cost-efectiveness model, including that all patients return to general population 
mortality and morbidity after a successful procedure; that all patients receive a matched sibling donor following an unsuc-
cessful engraftment; and that diferences in wait times exist between the treatments. Incorporating a number of changes to 
the model, the ERG’s base-case ICERs were £86,815 per QALY gained for  Strimvelis® compared with HSCT from a MUD 
and £16,704 per QALY gained compared with HSCT from a haploidentical donor (using a discount rate of 1.5%). The ICER 
for  Strimvelis® compared with HSCT from a MUD was highly sensitive to the diference in procedural mortality and could 
exceed NICE’s £100,000 per QALY gained threshold for HSTs, if HSCT survival rates have improved since the most recent 
data. The evaluation committee concluded that the most plausible ICERs were lower than £100,000 per QALY gained and 
that  Strimvelis® should be recommended for treatment of ADA-SCID where a matched related donor is unavailable.
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Key Points for Decision Makers 
The funding arrangements for  Strimvelis® were unknown 
at the time of appraisal and its cost was expected to luc-
tuate with the exchange rate.
The treatment beneit with  Strimvelis® was uncertain 
and the incremental cost-efectiveness ratio (ICER) for 
 Strimvelis® compared with haematopoietic stem cell 
transplant from a matched unrelated donor was very sen-
sitive to the assumed diference in procedural mortality 
between the treatments.
The Highly Specialised Technologies Evaluation Com-
mittee concluded that the most plausible ICERs were 
under £100,000 per quality-adjusted life-year gained and 
recommended  Strimvelis® for the treatment of adenosine 
deaminase deiciency–severe combined immunodei-
ciency where a matched related donor is unavailable.
1 Introduction
The National Institute for Health and Care Excellence 
(NICE) is an independent body that produces guidance and 
advice on health and social care in England. The Highly Spe-
cialised Technologies (HST) programme evaluates highly 
specialised treatments for very rare conditions. As part of the 
process, an Evidence Review Group (ERG) independently 
reviews clinical and economic evidence that is submitted 
by the company manufacturing the technology. It presents 
its critique for an independent Evaluation Committee which 
considers it alongside other evidence and makes recommen-
dations to NICE. Given the very small numbers of patients 
with the very rare conditions involved, the HST committee 
does not employ a simple utilitarian approach but must still 
give consideration to the balance between costs and beneits. 
Below a most plausible incremental cost-efectiveness ratio 
(ICER) of £100,000 per quality-adjusted life-year (QALY) 
gained, the decision to recommend the use of an HST is 
normally based on the cost-efectiveness estimate. Above a 
most plausible ICER of £100,000 per QALY gained, judge-
ments about the acceptability of the HST as an efective 
use of National Health Service (NHS) resources must take 
account of the magnitude of the incremental therapeutic 
improvement, as revealed through the number of additional 
QALYs gained [1].
This article summarises the ERG’s critique of the manu-
facturing company’s submission on  Strimvelis® (retroviral-
transduced autologous CD34+ cells) for treating adenosine 
deaminase deiciency–severe combined immunodeiciency 
(ADA-SCID). It also summarises issues that arose during 
the review and the committee’s decision-making. Full details 
of the appraisal and documents can be found on the NICE 
website [2].
2  The Decision Problem
ADA-SCID is a rare, inherited immune disorder, character-
ised by profound lymphopenia and impaired development 
and function of T cells, B cells and natural killer cells, as 
well as non-immunological defects [3]. Patients present with 
severe infections and failure to thrive [3] and are usually 
diagnosed within the irst year of life [4]. If infants with 
ADA-SCID receive no treatment to restore immune func-
tion, they will likely die before the age of 2 years [4].
There are very limited data available to estimate the inci-
dence of ADA-SCID in England, which is likely to be very 
low and concentrated within certain ethnicities in the UK 
[5]. Based on an estimate of 20 children per year present-
ing in the UK with any form of SCID [6], the company 
estimated that there would be three or fewer patients a year 
diagnosed with ADA-SCID in England.
There is no NICE clinical guidance on the management 
of ADA-SCID, although there are treatment guidelines from 
the European Society for Blood and Marrow Transplanta-
tion (EBMT) and European Society for Immunodeiciencies 
(ESID) [7]. The current preferred treatment is haematopoi-
etic stem cell transplant (HSCT) from a human leukocyte 
antigen (HLA) matched related donor (MRD) [7, 8]. Sur-
vival rates for ADA-SCID patients undergoing HSCT from 
an MRD were 86% for matched sibling donors (MSDs) and 
83% for matched family donors (MFDs) in the most recent 
published data at the time of the appraisal [3].
If no MRD is available, treatment options include gene 
therapy, HSCT from a matched unrelated donor (MUD), 
HSCT from a haploidentical donor and enzyme replace-
ment therapy (ERT) with polyethylene glycol-modified 
bovine adenosine deaminase (PEG-ADA) [7, 8]. The EBMT/
ESID guidelines recommend gene therapy in these cases 
[7] and there are ongoing trials of gene therapy treatments 
[8].  Strimvelis® is a gene therapy treatment licensed for use 
in patients with ADA-SCID for whom no MRD is avail-
able, and this was the patient population considered in the 
submission. It was given European Union (EU) marketing 
authorisation in May 2016 and was the irst EU-approved 
ex vivo gene therapy for paediatric patients. Cells from the 
patient’s own bone marrow are transduced to express ADA 
and, provided engraftment is successful, it is designed to 
be a single treatment with lifelong efects.  Strimvelis® is 
currently only available at the Hospital San Rafaele Tel-
ethon Institute for Gene Therapy in Milan, Italy. Treatment 
is only possible if patients can donate suicient CD34+ cells 
to deliver a minimum of 4 million puriied CD34+ cells/kg 
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for the manufacture of  Strimvelis® and a CD34+ stem cell 
back-up for use as a rescue treatment. In the clinical pathway 
presented, patients are initially maintained on intravenous 
immunoglobulin (IVIG) after treatment with  Strimvelis® 
or HSCT, and eventually discontinue IVIG if treatment is 
successful.
According to the submission,  Strimvelis® requires less 
pre-conditioning than HSCT from a MUD or haploidenti-
cal donor, does not carry the same risk of graft versus host 
disease (GvHD) and does not require the search for a donor 
that can delay HSCT from a MUD. GvHD is a complica-
tion associated with all types of allogenic HSCT. It is an 
immunological disorder that can be acute or chronic, and 
can afect many organs and cause death [9]. As gene therapy 
involves the patient’s own stem cells (autologous), the risk 
of GvHD is eliminated [10].
The comparator identiied by NICE was HSCT from a 
MUD or haploidentical donor. In the most recent published 
data on ADA-SCID patients, survival rates were 67% for 
HSCT from a MUD (1995–2009) and 71% for HSCT from 
a haploidentical donor (2000–2009) [3]. These treatments 
have a high morbidity and mortality risk associated with 
GvHD [3, 11]. HSCT from a MUD or haploidentical donor 
(but not normally MRD) usually requires chemotherapeutic 
pre-conditioning, although there is no consensus on condi-
tioning regimens [10, 12]. According to the submission, the 
low-dose busulfan conditioning used before treatment with 
 Strimvelis® would be associated with fewer adverse events 
than the full-dose chemotherapy regimens often used for 
HSCT from a MUD or haploidentical donor.
ERT with PEG-ADA is a non-curative and expensive 
treatment [8] which requires frequent injections and regular 
monitoring [10]. There is some uncertainty over long-term 
eicacy, as a study of nine patients receiving PEG-ADA 
for 5–12 years found that patients had subnormal immune 
function [13]. It is not approved in the EU and according to 
expert clinical advice is used only as a bridge to curative 
treatment in UK clinical practice, with patients initiated on 
PEG-ADA immediately following diagnosis of ADA-SCID 
while awaiting HSCT or gene therapy.
3  The Independent Evidence Review Group 
(ERG) Review
The company submitted evidence to NICE on the use of 
 Strimvelis® in patients with ADA-SCID. In accordance 
with HST procedures, the ERG had the opportunity to 
seek clariication on speciic issues in the submission and 
request additional information from the company. The ERG 
reviewed and critiqued this submission and checked for the 
existence of other evidence or alternative interpretations of 
the evidence.
3.1  Clinical Evidence
The company’s submission of evidence included a system-
atic review of studies on the use of  Strimvelis® and of the 
comparator treatments. Four open-label, single-arm trials of 
 Strimvelis® were identiied, as well as a long-term follow-up 
(LTFU) study of patients from these trials [14]. The sam-
ple sizes of the trials were very small, ranging from one to 
12 patients (with 17 of the 18 total patients enrolled in the 
LTFU). The evidence submitted by the company focused on 
an integrated population of the 18 patients that had received 
 Strimvelis® as part of these studies, with data pooled and 
treated as if it were from a single study. Data on some further 
patients receiving  Strimvelis® as part of a Named Patient 
Programme (NPP) were also provided but not included in 
the evidence synthesis or base-case cost-efectiveness analy-
sis. A historical comparator was used, with data on HSCT 
from a MUD or haploidentical donor in ADA-SCID patients 
based primarily on a multicentre, retrospective study, which 
provided the most recent survival data [3]. Some smaller 
case series and reports were also included in the narrative 
synthesis.
Overall survival in all 18 patients in the  Strimvelis® 
integrated population was 100%, with a median follow 
up of 6.95 years (range 2.3–13.4 years). Intervention-free 
survival was achieved in 14 of 17 patients (82.3%). Of the 
three patients in whom  Strimvelis® was unsuccessful, two 
underwent HSCT from an MSD and one received a second 
dose of  Strimvelis® and long-term PEG-ADA treatment.
Based on the main comparator study [3], overall survival 
for those receiving HSCT from a MUD was 67% (10/15) 
between 1995 and 2009. For HSCT from a haploidentical 
donor, overall survival was 71% (5/7) between 2000 and 
2009. Earlier data on HSCT from a haploidentical donor 
were not used in the comparison due to improvements in 
efectiveness of HSCT over time. Intervention-free survival 
data were limited for the comparator treatments, and it was 
not clear if available data were comparable with the data on 
 Strimvelis®.
Adverse events were similar for  Strimvelis® and the com-
parator treatments. All but one patient in the  Strimvelis® 
integrated population experienced a neurological, central 
nervous system or hearing event during treatment or follow-
up. A high incidence of non-immunological problems was 
also found in ADA-SCID patients following HSCT [15–19]. 
The company concluded that neither treatment appears to 
be efective in reducing non-immunological problems. The 
main diference in adverse events was that some patients 
experienced GvHD after HSCT [15, 17, 19–24], whereas 
no patients experienced this following treatment with 
 Strimvelis®.
Data were also presented on other outcomes, including 
immune function. Despite some variability across outcomes 
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and over time, generally data showed improved immune 
function with  Strimvelis®. For example, the severe infec-
tion rate declined, CD3+ T cell counts increased, and most 
patients that discontinued IVIG exhibited antibodies to a 
number of infectious antigens. There was a lack of compa-
rable data after HSCT from a MUD or haploidentical donor 
but both comparator treatments also appeared to improve 
immune function [3].
3.2  Critique of Clinical Evidence
The ERG highlighted a number of issues with the clinical 
evidence presented.
3.2.1  Study Design
The clinical evidence presented was based on open-label, 
single-arm trials with very small patient numbers and a his-
torical comparator. Studies and comparisons of this nature 
are inherently at high risk of bias and lack precision in esti-
mation of efects. Although the ERG considered this study 
design appropriate to evaluate clinical efectiveness due to 
the low incidence of ADA-SCID, there remained important 
limitations.
3.2.2  Evidence Synthesis
The ERG considered there to be suicient similarity between 
the studies that made up the  Strimvelis® integrated popula-
tion that pooling the data and treating them as if compris-
ing a single study was unlikely to lead to substantial bias. 
However, the ERG did not consider it appropriate to exclude 
data from the NPP from the narrative synthesis of clinical 
evidence, given the small sample size of the integrated and 
total population and the need to consider all available data.
3.2.3  Diferences with the Eligible Population
There were some concerns regarding how representative 
the  Strimvelis® integrated population was of ADA-SCID 
patients in England. There was a lack of clarity regarding 
numbers screened or excluded for some of the studies, mak-
ing it unclear if patients at greater risk had been excluded or 
whether other selection biases were present. No patients had 
been conirmed as having active viral infection at screen-
ing. Given the potential for viral infection in ADA-SCID 
patients, and expert clinical advice to the ERG that viral 
infection may be prognostic for success of treatment [11, 
25], the extent to which the data could be generalised to 
patients presenting with viral infections is unclear. The dura-
tion of PEG-ADA use by patients that received  Strimvelis® 
was longer than would be expected in UK practice, although 
there is no evidence that this is prognostic for success of 
subsequent treatment. Whilst noting these concerns, overall 
the ERG concluded that the data on  Strimvelis® were likely 
to be generalisable to England.
3.2.4  Survival Rates
Although overall survival was higher for  Strimvelis® than 
for the comparator treatments, the ERG believed there to 
be signiicant limitations to the data. Firstly, this evidence 
was based on small patient numbers so a small number of 
deaths could lead to substantial changes in survival esti-
mates. Secondly, the historical data on overall survival fol-
lowing HSCT likely relect an underestimate of the current 
efectiveness of these treatments, due to the small sample 
sizes, new techniques in allogeneic HSCT [8] and improved 
survival rates in more recent data on HSCT in patients with 
other conditions [26, 27]. There have been improvements 
in matching of donors, infection control procedures, inten-
sity of conditioning and provision of supportive care [27]. 
Thirdly, the overall survival rate overestimated the efective-
ness of  Strimvelis®, since when treatment failed but patients 
did not die due to receiving an alternative treatment, they 
were still counted as a treatment success. In the view of the 
ERG, the intervention-free survival rate provided a better 
assessment of clinical efectiveness, as also noted by the 
European Medicines Agency [28].
3.2.5  Adverse Events
There were limitations in the reporting of GvHD follow-
ing HSCT. Estimates were based on very small case reports 
(ranging from one to seven patients) and deinitions and 
reporting of GvHD in these studies varied. Data from stud-
ies from diferent centres and time periods were pooled as if 
from a single study rather than using meta-analytic methods. 
Regarding  Strimvelis®, leukaemia-like lymphoproliferative 
disorders have been identiied in patients with other forms of 
SCID after gene therapy due to the vector being integrated 
near an oncogene [29, 30]. Although no similar events have 
been observed in ADA-SCID, the small numbers of patients 
who have received  Strimvelis® mean this cannot yet be ruled 
out as an important potential risk.
3.3  Cost‑Efectiveness Evidence
The cost-efectiveness evidence provided by the company 
included a review of published data on health-related qual-
ity of life (HRQoL) and a de novo economic evaluation, 
comparing  Strimvelis® to either HSCT from a MUD or hap-
loidentical donor in a hypothetical cohort of patients aged 
1 year old. The model consisted of a decision tree to estab-
lish the proportion of patients surviving the initial transplant 
procedure and the proportion requiring rescue transplant 
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in the irst 3 years, combined with a Markov modelling 
approach to extrapolate costs and quality-adjusted survival 
over a lifetime time horizon. The four main outcomes from 
the model were (1) success, long-term survival; (2) unsuc-
cessful engraftment; (3) death; and (4) long-term survival 
after rescue HSCT.
The model assumed patients would receive PEG-ADA 
treatment while awaiting initial or rescue transplant proce-
dures, and incorporated post-procedure IVIG use and risk 
of severe infection for any transplant procedure and GvHD 
for HSCT. Rescue transplants were assumed to be HSCT 
from an MSD (e.g. a new sibling born since the decision to 
undergo treatment with  Strimvelis®) and to occur 2 years 
after the initial procedure, with no risks of death, GvHD or 
failure to engraft. It was assumed that the decision to use 
 Strimvelis® would be made before the search for a MUD, 
and that HSCT from a haploidentical donor would only be 
used if a MUD was unavailable. Patients who survived trans-
plant procedures were assumed to return to the mortality and 
morbidity risk of the general population. The company’s 
model structure is presented in Fig. 1.
The model characterised three main beneits of treatment 
with  Strimvelis®: (1) reduced duration of ERT with PEG-
ADA before the initial transplant procedure; (2) reduced pro-
cedural mortality; and (3) avoidance of GvHD. The model 
also assumed diferent rates of rescue transplant between 
treatment arms.
The company model assumed overall survival of 100% 
with  Strimvelis®, 66.67% with HSCT from a MUD and 
71.4% with HSCT from a haploidentical donor, based on 
data from the  Strimvelis® integrated population and Has-
san et al. [3] as the historical comparator. Rates of rescue 
transplant following failure to engraft were assumed to be 
17.6, 6.7 and 28.6%, respectively. GvHD was assumed to 
occur in approximately one-third of patients undergoing an 
initial HSCT procedure, while there was assumed to be no 
risk of GvHD with  Strimvelis®. HRQoL was assumed equal 
to that of the general population, with decrements applied 
for 6 months in patients recovering from transplant proce-
dures and in patients experiencing GvHD. The perspective 
of the company’s analysis was the NHS and Personal Social 
Services (NHS & PSS).
The company argued that a discount rate of 1.5% should 
be applied to costs and health outcomes, on the basis that 
 Strimvelis® restores people to full or near full health over a 
long time period who would have otherwise died or had a 
very severely impaired life. The company base case found 
 Strimvelis® to be more costly and more efective than the 
comparators. The deterministic ICERs were £36,360 per 
QALY gained for  Strimvelis® compared with HSCT from a 
Fig. 1  Schematic of the company’s model structure. ADA-SCID 
adenosine deaminase deiciency–severe combined immunodeiciency, 
GvHD graft versus host disease, HSCT haematopoietic stem cell 
transplant, IVIG intravenous Immunoglobulin, MRD matched related 
donor, MSD matched sibling donor, PEG-ADA polyethylene glycol-
modiied bovine adenosine deaminase
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MUD and £14,645 per QALY gained for  Strimvelis® com-
pared with HSCT from a haploidentical donor. The ICERs 
remained below the £100,000 per QALY lower tier thresh-
old that NICE considers appropriate for HSTs [1], across a 
range of one- and two-way sensitivity analyses and scenario 
analyses.
3.4  Critique of Cost‑Efectiveness Evidence
The ERG highlighted a number of issues with the cost-efec-
tiveness evidence presented by the company.
3.4.1  Position of  Strimvelis® in the Treatment Pathway
The ERG was concerned that the model did not include 
alternative points in the treatment pathway at which a deci-
sion to use  Strimvelis® may be taken. The company model 
applied only to patients for whom the decision is taken 
immediately following diagnosis, thus avoiding a search for 
a MUD for all patients (where a search includes a database 
search, followed by contacting and testing potential donors). 
The ERG considered that for some patients the decision to 
use  Strimvelis® may be taken only after a search for a MUD 
has been completed, including those unwilling to travel to 
Milan if alternative treatment is available.
3.4.2  Health Gains with  Strimvelis®
The ERG believed that the respective 33 and 29 percent-
age point reductions in procedural mortality with  Strimvelis® 
compared with HSCT from a MUD or haploidentical donor 
applied in the submission may represent the upper limit of 
additional beneit from  Strimvelis®. This was due to the 
likely improvements in survival from HSCT and the use 
of overall survival rather than intervention-free survival to 
characterise the eicacy of  Strimvelis®.
The ERG thought it was unrealistic to assume that 
patients with ADA-SCID who survive an initial transplant 
procedure (either  Strimvelis® or HSCT) return to the same 
level of health and life expectancy as the general population. 
The ERG felt that this would overestimate quality-adjusted 
survival and underestimate healthcare costs due to the cogni-
tive and neurological deicits of ADA-SCID, such as bilat-
eral hearing impairment, and potential long-term adverse 
events associated with pre-transplant conditioning regimens. 
Of similar concern was the assumption of 100% success and 
survival with rescue transplant, which overestimates quality-
adjusted survival and underestimates the healthcare costs in 
patients that fail to engraft following the initial procedure. 
These factors caused the company model to overestimate the 
health beneit from reductions in procedural mortality and 
underestimate subsequent costs.
3.4.3  Treatment Costs Associated with  Strimvelis® 
and HSCT
The ERG identified a number of costs associated with 
 Strimvelis® that were omitted from the company base case. 
These included NHS-supported travel costs to and from 
Milan, the cost of screening patients deemed unable to pro-
duce suicient CD34+ cells, additional hospitalisation costs 
for patients whose length of stay exceeds 55 days and trans-
plantation of back-up bone marrow after treatment failure or 
to facilitate recovery.
The cost per HSCT from a MUD and GvHD event in the 
company base case appeared to have been overestimated. For 
HSCT, the company applied a unit cost taken from the NHS 
main schedule of reference costs speciic to cord blood trans-
plants (£95,517). The majority of stem cell transplants are 
sourced from bone marrow, which was the comparator noted 
in the scope, and which has a lower average cost in the NHS 
schedule (£79,199) than cord blood transplants [3, 31]. The 
unit cost applied to GvHD events of any severity in the model 
was the mean diference in hospital readmission costs between 
patients without GvHD and those with severe (grade III/IV) 
GvHD [32]. The same study provided a cost estimate for any 
GvHD event, which the ERG deemed more appropriate.
The ERG had concerns about the company’s assumed 
10-week differential in wait times between  Strimvelis® 
(9  weeks) and HSCT (19  weeks). The wait time for 
 Strimvelis® was based on the clinic schedule. During clari-
ication the ERG requested information on the observed 
wait time among patients in the integrated population. The 
company response indicated that the average wait time was 
5.7 months between the decision to use  Strimvelis® and 
receipt of  Strimvelis®.
The ERG identiied two potentially relevant uncertainties in 
the product cost of  Strimvelis®. First, it was unclear whether 
value-added tax (VAT) should be added to the ixed price in 
euros agreed between the company and NHS England. VAT 
may be payable dependent on whether a patient arrives in Milan 
via the S2 or EU directive route, and this was not decided at the 
time of appraisal. Second, the ERG deemed that the uncertainty 
in the exchange rate warranted consideration.
3.4.4  Preferred Base Case
The ERG made a number of changes to the company model, 
combining scenario analyses provided by the company with 
those formed by the ERG, as shown in Table 1.
The ERG’s base case predicted lower QALYs for all three 
treatments than the company base case. This was due to 
increased mortality and morbidity associated with rescue 
transplants and the application of HRQoL decrements for 
IVIG use and bilateral hearing impairment in patients suc-
cessfully treated with HSCT or  Strimvelis®. It predicted 
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higher costs for  Strimvelis® and HSCT from a haploiden-
tical donor and lower costs for HSCT from a MUD. This 
was attributable to a correction in the calculation of rates of 
rescue transplant, combined with increased healthcare costs 
per rescue transplant to relect risks of severe infection and 
GvHD, and the lower unit cost for HSCT from a MUD.
The ERG’s base-case ICERs were higher than those esti-
mated by the company, at £86,815 per QALY gained for 
 Strimvelis® compared with HSCT from a MUD and £16,704 
per QALY gained compared with a haploidentical donor using 
a discount rate of 1.5%. Using the NICE reference case 3.5% 
discount rate, the ICER for  Strimvelis® compared with HSCT 
from a MUD was £147,834 per QALY gained and £28,503 
per QALY gained when compared with HSCT from a hap-
loidentical donor. The ICER for  Strimvelis® compared with 
HSCT from a MUD was very sensitive to the assumed dif-
ference in procedural mortality between the two treatments. 
 Strimvelis® must reduce procedural mortality by at least 30 
percentage points compared with HSCT from a MUD in order 
for the ICER to remain below £100,000 per QALY gained 
when using a 1.5% discount rate. The ICER was also sensi-
tive to the rates of rescue transplants and the additional cost of 
 Strimvelis®. The ICERs for  Strimvelis® compared with HSCT 
from a MUD or haploidentical donor increased if search costs 
for a MUD are not avoided prior to  Strimvelis® treatment. It 
was anticipated that the ICERs for  Strimvelis® compared with 
HSCT from a MUD or haploidentical donor may increase in 
patients that have a worse prognosis, including older patients 
and patients with active viral infection.
3.5  Conclusions of the ERG’s Review
Overall survival was 100% for  Strimvelis®, substantially 
higher than historical comparator data, and intervention-free 
Table 1  Scenario analyses included in the Evidence Review Group base case
ADA-SCID adenosine deaminase deiciency–severe combined immunodeiciency, ERG Evidence Review Group, GvHD graft versus host disease, HRQoL 
health-related quality of life, HSCT haematopoietic stem cell transplant, ICER incremental cost-efectiveness ratio, IVIG intravenous Immunoglobulin, 
MSD matched sibling donor, MUD matched unrelated donor, NPP Named Patient Programme, PEG-ADA polyethylene glycol-modiied bovine adenosine 
deaminase
ERG base case
Company scenarios preferred by the ERG
 Utility weight of 0.75 applied for patients treated with IVIG
 Duration of GvHD of 2 years consistent with timing of rescue transplant
 Revised PEG-ADA dose determined by patient weight
 Revised administration costs for PEG-ADA and IVIG
 Inclusion of travel costs to and from Milan
ERG scenarios
 (i) Corrections to the company model
 (ii) Incorporating the NPP to inform procedural outcomes
 (iii) Assuming equal wait times and pre-procedure PEG-ADA use across treatment arms
 (iv) Assuming rescue therapy has same cost and health outcomes as initial MUD
 (v) Adding ongoing healthcare costs and morbidity associated systemic sequelae of ADA-SCID
 (vi) Adjusting unit costs for HSCT from a MUD and GvHD events
 (vii) Incorporating cost of baseline screening for proportion of patients ineligible for  Strimvelis®
ERG’s justiication of alternative revisions
 (i) Rescue transplant probabilities must be conditional on patients surviving initial transplant and minor typographical errors in the post-
Strimvelis® follow-up costs in the irst 6 months and the cost per vector copy number require corrections
 (ii) Important to use all available data on the eicacy of  Strimvelis® to inform the model parameters. Incorporating the NPP is consistent with 
the company’s methods of informing outcomes
 (iii) Insuicient evidence exists supporting the company’s claim for a diferential in wait times
 (iv) Unrealistic to assume all rescue transplants would ind a MSD, and that all transplants would achieve 100% survival with 100% success-
ful engraftment
 (v) Evidence suggests that patients with ADA-SCID do not experience general population mortality and HRQoL after successful treatment
 (vi) MUD transplants should be costed by the expected transplant type (i.e. bone marrow vs. cord donor) and GvHD costs should be based on 
all events rather than severe cases only
 (vii) Costs for screening for patients unable to donate adequate CD34+ cells should be incorporated into the model
ERG revised base-case MUD ICER £86,815 per QALY gained
ERG revised base-case haploidentical ICER £16,704 per QALY gained
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survival was 82.3%. However, the ERG was concerned that 
the extent of the estimated treatment beneit is highly uncer-
tain due to the small patient numbers. The ERG considered 
that the company base case omitted potentially important 
costs associated with the use of  Strimvelis® and may have 
overestimated some costs associated with the comparator 
treatments. The ERG was also concerned by some of the 
assumptions in the model, in particular that all patients who 
survive the initial procedure are cured and return to general 
population mortality and morbidity. The ERG’s preferred 
base case suggested that  Strimvelis® is cost efective, with 
respect to NICE’s £100,000 lower tier threshold for HSTs, 
for patients that have no MUD available and in whom HSCT 
from a haploidentical donor is the only alternative. However, 
improvements in techniques that increase overall survival 
after HSCT from a MUD or the occurrence of a death in a 
patient treated with  Strimvelis® could cause the ICER for 
 Strimvelis® compared with HSCT from a MUD to exceed 
£100,000 per QALY gained.
4  National Institute for Health and Care 
Excellence (NICE) Guidance
The HST Evaluation Committee considered the ERG report 
alongside evidence submitted by the manufacturer and the 
views of parents or carers of patients, patient representatives 
and clinical experts [33].
The committee considered the approach to the clinical 
efectiveness evidence taken by the company to be appropri-
ate. Despite uncertainty on overall survival, it was decided 
that survival rates are higher with  Strimvelis® than the com-
parators and that data on intervention-free survival, while 
important, cannot easily be compared with HSCT. In terms 
of diferences with the eligible population, the committee 
concluded that patients in clinical practice may be younger 
than those in the evidence presented, potentially leading to 
greater eicacy.
The committee disagreed with the ERG on the position 
of  Strimvelis® in the treatment pathway, after hearing from 
clinical experts that they would perform a database search 
for a MUD (but not contact and test donors) before the deci-
sion to use  Strimvelis® is made. A database search is quick, 
with the main costs and wait time of inding a MUD incurred 
during contacting and testing potential donors. The com-
mittee also heard from experts that it would not be possible 
to receive  Strimvelis® as a rescue treatment after failure of 
HSCT and so concluded that the pathway used by the com-
pany was appropriate.
The committee agreed with the company that it was 
appropriate to exclude data from the NPP from the eco-
nomic model due to diferences with the population likely 
to receive  Strimvelis® in clinical practice, and that costs 
associated with bilateral hearing impairment should not be 
included. It also decided that a higher survival rate from 
HSCT with a MUD should be used to relect the uncertainty 
and likely underestimate of the historical comparator data 
Table 2  Committee base case: 
estimated costs, efects and cost 
efectiveness (discounted 1.5%)
GvHD graft versus host disease, HSCT haematopoietic stem cell transplant, HSR-TIGET Hospital San Raf-
faele Telethon Institute for Gene Therapy, ICER incremental cost-efectiveness ratio, IVIG intravenous 
immunoglobulin, MUD matched unrelated donor, PEG-ADA polyethylene glycol-modiied bovine adeno-
sine deaminase, QALYs quality-adjusted life-years
a All GvHD costs associated with  Strimvelis® emanate from MUD rescue therapy transplants assumed in 
the committee base-case model (which have an associated GvHD risk)
Base case Strimvelis® HSCT MUD HSCT haploidentical
Costs
 Product £505,000
 Screening pre-procedure £161 £45,127 £45,127
 Initial hospitalisation/transplant £92,217 £81,973 £108,760
 Rescue PEG-ADA/transplant £339,955 £203,973 £815,893
 Severe infection £12,786 £9310 £8600
 IVIG £17,977 £12,863 £15,147
 GvHD £635a £5089 £6376
 Follow-up £65,457 £46,792 £58,502
 Travel to HSR-TIGET in Milan £1412 £0 £0
 Total £1,035,601 £405,126 £1,058,405
Efects
 QALYs 31.3 22.8 19.7
Cost efectiveness
 ICER per QALY gained £74,430 Dominated
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[3], and agreed on a value of 72.5%. Table 2 presents the 
associated costs, efects and cost efectiveness in the com-
mittee’s preferred model.
The committee had concerns about whether  Strimvelis® 
fulilled NICE’s criteria for using a 1.5% discount rate [1] 
and considered both a 1.5% and 3.5% rate. The analysis 
using the committee’s preferred assumptions with a 1.5% 
discount rate gave ICERs of £74,430 per QALY gained 
for  Strimvelis® compared with HSCT from a MUD and 
 Strimvelis® was dominant when compared with HSCT from 
a haploidentical donor. Using a 3.5% discount rate, the ICER 
for  Strimvelis® compared with HSCT from a MUD was 
£120,506 per QALY gained and £12,106 per QALY gained 
for  Strimvelis® compared with HSCT from a haploidentical 
donor. The committee also considered a scenario in which 
rescue rates were equal between treatments; the ICERs for 
 Strimvelis® compared with HSCT from a MUD were lower 
in this scenario and the ICERs for  Strimvelis® compared 
with a haploidentical donor remained under £100,000 per 
QALY gained. As the committee believed  Strimvelis® ofers 
undiscounted QALY gains of at least 14.0 compared with 
HSCT from a MUD, they applied a QALY weighting of 1.4 
to this comparison, in accordance with the HST programme 
process [1].
The committee believed that the most plausible ICERs 
for  Strimvelis® compared with HSCT from a MUD or hap-
loidentical donor were lower than the £100,000 per QALY 
gained threshold. While acknowledging the high cost of 
 Strimvelis® and some uncertainty in both the clinical and 
cost-efectiveness evidence provided, the committee consid-
ered  Strimvelis® to be an efective treatment that provides 
value for money.
After consultation on preliminary guidance, NICE issued 
the following inal guidance on the use of  Strimvelis®:
“Strimvelis is recommended, within its marketing author-
isation, as an option for treating adenosine deaminase dei-
ciency–severe combined immunodeiciency (ADA–SCID) 
when no suitable human leukocyte antigen-matched related 
stem cell donor is available” [34].
5  ERG Conclusion
This HST evaluation highlighted the importance of recom-
mendations being informed by an independent ERG critique 
of the evidence. In this case, the ERG identiied several 
important limitations to the data presented and was able to 
critique the economic model and provide additional analyses 
using the best available evidence.
There were a number of general issues arising from 
the HST evaluation which may be of importance in other 
cases, including evaluations of other gene therapy treat-
ments. Firstly, it highlighted the challenges of appraising 
clinical and cost-efectiveness evidence on very rare con-
ditions. Conclusions were highly sensitive to the interpre-
tation of very limited data. Evidence on  Strimvelis® relied 
on single-arm studies with very small patient numbers and 
historical comparator data. This resulted in a high level 
of uncertainty both in terms of the inherent risk of bias 
associated with this study design and a lack of precision 
due to small sample sizes for both  Strimvelis® and histori-
cal comparators. Each patient treated could have a large 
inluence on estimates of overall survival and treatment 
success. Given the rarity of the disease, there were also 
some issues with the representativeness of the population 
that had received  Strimvelis® to the eligible population in 
England. While there is a well-developed methodologi-
cal literature for evaluating randomised controlled trials 
in much larger patient populations, there is less guidance 
on assessing study designs most appropriate for evaluat-
ing specialised technologies in rare conditions. Therefore, 
extensive relection and careful judgement were required 
to assess whether appropriate methods were used to mini-
mise confounding and other biases.
Secondly, it highlighted the value of up-to-date pub-
lished data on treatment outcomes for rare conditions, 
particularly in treatments such as HSCT where outcomes 
are improving rapidly. Obtaining contemporary evidence 
to inform survival rates was challenging and an update 
to the latest analysis would have been very valuable in 
determining whether  Strimvelis® could be considered cost 
efective. It also emphasised the importance of consulting 
with experts in the relevant ield of medicine to obtain 
up-to-date survival estimates.
Thirdly, it raised questions over the relative usefulness 
of overall survival as a key outcome, when relying on 
small, single-arm trials of this nature. Some patients were 
counted as a treatment success despite having to receive an 
alternative treatment, without which they may have died. 
The ERG considered the intervention-free survival rate to 
be a better assessment of efectiveness.
Finally, the ERG raised the possibility of  Strimvelis® 
being ofered at a diferent point in the treatment pathway, 
if the requirement to move temporarily to Milan acted as 
a barrier to some families. This may be particularly rel-
evant in other cases where treatment is provided in another 
country. The critique of the cost-efectiveness evidence 
also raised issues around the costs of travel to Italy and 
uncertainties around treatment costs due to exchange rates 
and VAT.
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